Single-institution experience with gemcitabine–cisplatin combination therapy as a second-line treatment for patients with unresectable biliary tract cancer after failure of gemcitabine–S-1 combination therapy: a prospective feasibility study-Reference-Cited by-同舟云学术

Single-institution experience with gemcitabine–cisplatin combination therapy as a second-line treatment for patients with unresectable biliary tract cancer after failure of gemcitabine–S-1 combination therapy: a prospective feasibility study

Published:2018-03-28 Issue:5 Volume:81 Page:949-955
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Matsuyama Ryusei^ORCID,Morioka Daisuke,Mori Ryutaro,Hiratani Seigo,Yabushita Yasuhiro,Ota Yohei,Kumamoto Takafumi,Taniguchi Koichi,Endo Itaru

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/article/10.1007/s00280-018-3566-z/fulltext.html

Reference29 articles.

1. Gores GJ (2003) Cholangiocarcinoma: current concepts and insight. Hepatology 37:961–969

2. Rajagopalan V, Daines WP, Grossbard ML et al (2004) Gallbladder and biliary tract carcinoma: a comprehensive up date, Part 1. Oncology 18:889–896

3. Matsuda T, Marugame T (2007) International comparisons of cumulative risk of gallbladder cancer and other biliary tract cancer, from cancer incidence in five continents. Jpn J Clin Oncol 37:74–75

4. Randi G, Malvezzi M, Levi F et al (2009) Epidemiology of biliary tract cancers: an update. Ann Oncol 20:146–159

5. Leonard GD, O’Reilly EM (2005) Biliary tract cancer: current concepts and controversies. Expert Opin Pharmacother 6:211–223

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical outcomes for previously treated patients with advanced biliary tract cancer: a meta-analysis;Future Oncology;2024-04

2. The inhibitory effects of lobaplatin, or in combination with gemcitabine on triple-negative breast cancer cells in vitro and in vivo;Oncologie;2023-01-01

3. Second-line treatments in advanced biliary tract cancer: systematic literature review of efficacy, effectiveness and safety;Future Oncology;2022-06

4. NLRP3 augmented resistance to gemcitabine in triple-negative breast cancer cells via EMT/IL-1β/Wnt/β-catenin signaling pathway;Bioscience Reports;2020-07

5. Combination versus mono-therapy as salvage treatment for advanced biliary tract cancer: A comprehensive meta-analysis of published data;Critical Reviews in Oncology/Hematology;2019-07